Eruptive keratoacanthomas secondary to nivolumab immunotherapy

被引：15
|
作者：
Bednarek, Robert [1 ]
Marks, Katherine [1 ]
Lin, George [2 ]
机构：
[1] Geisinger Med Ctr, Dept Dermatol, Danville, PA 17822 USA
[2] Geisinger Med Ctr, Dept Pathol, Div Dermatopathol, Danville, PA 17822 USA
来源：
INTERNATIONAL JOURNAL OF DERMATOLOGY | 2018年 / 57卷 / 03期
关键词：
THERAPY;
D O I：
10.1111/ijd.13893
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：E28 / E29
页数：2
相关论文
共 35 条
  • [1] Eruptive keratoacanthomas and leflunomide
    Schmutz, J. -L.
    ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, 2016, 143 (04): : 330 - 331
  • [2] Sorafenib-induced multiple eruptive keratoacanthomas
    Jantzem, H.
    Dupre-Goetghebeur, D.
    Spindler, P.
    Merrer, J.
    ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, 2009, 136 (12): : 894 - 897
  • [3] Eruptive porokeratosis under nivolumab adjuvant treatment for melanoma
    Cinotti, Elisa
    Fiorani, Diletta
    Provvidenziale, Luca
    Miracco, Clelia
    Calamai, Vanessa
    Danielli, Riccardo
    Rubegni, Pietro
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2019, 58 (07) : E138 - E140
  • [4] Self-Resolving Eruptive Keratoacanthomas After Full-Field Erbium Laser Resurfacing
    Axibal, Eileen L.
    Kreger, Julia D.
    Contreras, Michael E.
    Cohen, Joel L.
    JOURNAL OF DRUGS IN DERMATOLOGY, 2016, 15 (11) : 1453 - 1455
  • [5] Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab
    Riaz, Nadeem
    Havel, Jonathan J.
    Makarov, Vladimir
    Desrichard, Alexis
    Urba, Walter J.
    Sims, Jennifer S.
    Hodi, F. Stephen
    Martin-Algarra, Salvador
    Mandal, Rajarsi
    Sharfman, William H.
    Bhatia, Shailender
    Hwu, Wen-Jen
    Gajewski, Thomas F.
    Slingluff, Craig L., Jr.
    Chowell, Diego
    Kendall, Sviatoslav M.
    Chang, Han
    Shah, Rachna
    Kuo, Fengshen
    Morris, Luc G. T.
    Sidhom, John-William
    Schneck, Jonathan P.
    Horak, Christine E.
    Weinhold, Nils
    Chan, Timothy A.
    CELL, 2017, 171 (04) : 934 - +
  • [6] Immunotherapy for Urothelial Carcinoma: Focus on Clinical Utility of Nivolumab
    Chiang, Ryan S.
    Glover, Michael J.
    Khaki, Ali Raza
    Srinivas, Sandy
    ONCOTARGETS AND THERAPY, 2022, 15 : 1259 - 1269
  • [7] Tailored Immunotherapy Approach With Nivolumab in Advanced Transitional Cell Carcinoma
    Grimm, Marc-Oliver
    Schmitz-Draeger, Bernd Juergen
    Zimmermann, Uwe
    Gruen, Christine Barbara
    Baretton, Gustavo Bruno
    Schmitz, Marc
    Foller, Susan
    Leucht, Katharina
    Schostak, Martin
    Zengerling, Friedemann
    Schumacher, Ulrike
    Loidl, Wolfgang
    Meran, Johannes
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (19) : 2128 - +
  • [8] Pharmacological combination of nivolumab with dendritic cell vaccines in cancer immunotherapy: An overview
    Calmeiro, Joao
    Carrascal, Mylene A.
    Ramos Tavares, Adriana
    Alexandre Ferreira, Daniel
    Gomes, Celia
    Teresa Cruz, Maria
    Falcao, Amilcar
    Miguel Neves, Bruno
    PHARMACOLOGICAL RESEARCH, 2021, 164
  • [9] Immunotherapy with nivolumab for the treatment of soft tissue sarcoma with pulmonary metastasis: A case report
    Puty, Taynah C.
    Franca, Tiago G.
    Oliveira, Paula B. T.
    Carvalho, Luis Eduardo W.
    Yamaguchi, Nise H.
    MOLECULAR AND CLINICAL ONCOLOGY, 2020, 13 (02) : 191 - 194
  • [10] The Role of the Pharmacist in Optimizing Cancer Immunotherapy: A Retrospective Study of Nivolumab Adverse Events
    Menz, Bradley D.
    Johnson, Jacinta L.
    Gillard, Davina F.
    Chong, William
    Ward, Michael B.
    JOURNAL OF PHARMACY PRACTICE, 2021, 34 (03) : 386 - 396
1234